CA2286003C - Phosphate-binding polymer preparation - Google Patents
Phosphate-binding polymer preparation Download PDFInfo
- Publication number
- CA2286003C CA2286003C CA002286003A CA2286003A CA2286003C CA 2286003 C CA2286003 C CA 2286003C CA 002286003 A CA002286003 A CA 002286003A CA 2286003 A CA2286003 A CA 2286003A CA 2286003 C CA2286003 C CA 2286003C
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- phosphate
- tablet
- inclusively
- binding polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 102
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 title claims abstract description 93
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title abstract description 28
- 239000002245 particle Substances 0.000 claims abstract description 35
- 229920002678 cellulose Polymers 0.000 claims abstract description 28
- 239000001913 cellulose Substances 0.000 claims abstract description 28
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 23
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 14
- 239000010452 phosphate Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 60
- -1 inclusively Chemical group 0.000 claims description 38
- 125000003282 alkyl amino group Chemical group 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 229920001577 copolymer Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920000083 poly(allylamine) Polymers 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 230000004580 weight loss Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229910001410 inorganic ion Inorganic materials 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-M 3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 229940099352 cholate Drugs 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 2
- 239000011369 resultant mixture Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 2
- 201000005991 hyperphosphatemia Diseases 0.000 abstract description 4
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 238000003756 stirring Methods 0.000 abstract description 3
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 201000006370 kidney failure Diseases 0.000 abstract description 2
- 230000033001 locomotion Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 63
- 239000000203 mixture Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 230000003068 static effect Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007941 film coated tablet Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229920003114 HPC-L Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8658197 | 1997-04-04 | ||
| JP86581/1997 | 1997-04-04 | ||
| PCT/JP1998/001536 WO1998044933A1 (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2286003A1 CA2286003A1 (en) | 1998-10-15 |
| CA2286003C true CA2286003C (en) | 2007-06-05 |
Family
ID=13890981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002286003A Expired - Lifetime CA2286003C (en) | 1997-04-04 | 1998-04-03 | Phosphate-binding polymer preparation |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6383518B1 (enExample) |
| EP (2) | EP1304104B1 (enExample) |
| JP (2) | JP2009173687A (enExample) |
| KR (1) | KR100456202B1 (enExample) |
| CN (1) | CN1180782C (enExample) |
| AT (2) | ATE364377T1 (enExample) |
| AU (1) | AU726142B2 (enExample) |
| CA (1) | CA2286003C (enExample) |
| CY (1) | CY1106823T1 (enExample) |
| DE (2) | DE69837945T2 (enExample) |
| DK (1) | DK1304104T3 (enExample) |
| ES (2) | ES2201463T3 (enExample) |
| PT (1) | PT1304104E (enExample) |
| TW (1) | TW592727B (enExample) |
| WO (1) | WO1998044933A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| JP3718341B2 (ja) | 1998-05-12 | 2005-11-24 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースとその製造方法 |
| TW568788B (en) | 1998-10-12 | 2004-01-01 | Chugai Pharmaceutical Co Ltd | Polymer combining with phosphoric acid and preparation containing the same |
| AU778262B2 (en) * | 1999-10-19 | 2004-11-25 | Genzyme Corporation | Direct compression polymer tablet core |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US6680069B1 (en) | 1999-11-09 | 2004-01-20 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose and process for manufacturing the same |
| JP3552160B2 (ja) | 2000-01-14 | 2004-08-11 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース粒子の形成方法 |
| WO2002066543A1 (en) | 2001-02-16 | 2002-08-29 | Genzyme Corporation | Method of drying a material having a cohesive phase |
| WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
| BR0209020A (pt) | 2001-04-18 | 2004-08-10 | Genzyme Corp | Composição farmacêutica de polialilamina |
| ES2637020T3 (es) | 2001-04-18 | 2017-10-10 | Genzyme Corporation | Uso de polímero de amina para reducir la glucosa sérica |
| FR2827771B1 (fr) * | 2001-07-25 | 2003-10-24 | Apis Spheromont | Formulation et procede de preparation de spheroides pouvant etre fortement titres et a dispersion rapide |
| US6600011B2 (en) | 2001-10-09 | 2003-07-29 | Genzyme Corporation | Process for purification and drying of polymer hydrogels |
| TWI231760B (en) * | 2001-12-20 | 2005-05-01 | Chugai Pharmaceutical Co Ltd | Coated lozenge and manufacturing method thereof |
| US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| EP1869090A1 (en) * | 2005-03-16 | 2007-12-26 | Council Of Scientific And Industrial Research | An improved process for the preparation of crosslinked polyallylamine polymer. |
| JP2009507019A (ja) * | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| KR101547925B1 (ko) | 2005-09-15 | 2015-08-27 | 젠자임 코포레이션 | 아민 중합체에 대한 샤셋 제형 |
| MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| GB0601899D0 (en) * | 2006-01-31 | 2006-03-08 | Ineos Silicas Ltd | Compositions |
| EP1818048B1 (en) * | 2006-02-14 | 2009-01-07 | Teva Pharmaceutical Industries, Inc. | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture |
| WO2007094779A1 (en) * | 2006-02-14 | 2007-08-23 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture |
| JP2009536246A (ja) * | 2006-05-05 | 2009-10-08 | ゲンズイメ コーポレーション | ホスフェート捕捉剤としてのアミン縮合重合体 |
| CA2658338A1 (en) * | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| US7964182B2 (en) | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| BRPI0717008A2 (pt) * | 2006-09-01 | 2014-01-21 | Usv Ltd | Processo para o preparo de cloridrato de sevelamer e formulação do mesmo |
| WO2008042222A2 (en) | 2006-09-29 | 2008-04-10 | Genzyme Corporation | Amide dendrimer compositions |
| WO2008076242A1 (en) | 2006-12-14 | 2008-06-26 | Genzyme Corporation | Amido-amine polymer compositions |
| EP2114376A1 (en) * | 2007-02-23 | 2009-11-11 | Genzyme Corporation | Amine polymer compositions |
| WO2008109095A1 (en) * | 2007-03-08 | 2008-09-12 | Genzyme Corporation | Sulfone polymer compositions |
| US20100166696A1 (en) * | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
| WO2009034540A1 (en) * | 2007-09-11 | 2009-03-19 | Ranbaxy Laboratories Limited | Pharmaceutical composition of sevelamer |
| GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| JP2011506449A (ja) * | 2007-12-14 | 2011-03-03 | ジェンザイム コーポレーション | コーティング医薬組成物 |
| WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| AU2010209293A1 (en) * | 2009-01-22 | 2011-09-08 | Usv Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
| US20100330175A1 (en) * | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
| WO2010149794A2 (en) | 2009-06-26 | 2010-12-29 | Combino Pharm, S.L. | Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) |
| GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| DK2490675T3 (en) * | 2009-10-22 | 2019-04-29 | Synthon Bv | Pharmaceutical compositions with sevelamer |
| GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
| EP2545907A1 (en) | 2011-07-15 | 2013-01-16 | Combino Pharm, S.L. | Aqueous wet granulation process for cross-linked polyallylamine polymers |
| MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| WO2016135065A1 (en) * | 2015-02-23 | 2016-09-01 | Amneal Pharmaceuticals Company Gmbh | Process for granulating sevelamer carbonate |
| WO2018124264A1 (ja) | 2016-12-28 | 2018-07-05 | 富士フイルム株式会社 | 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法 |
| JP6992084B2 (ja) | 2017-10-16 | 2022-01-13 | 富士フイルム株式会社 | 高リン血症治療剤 |
| CA3079171C (en) * | 2017-10-16 | 2023-09-12 | Fujifilm Corporation | Therapeutic agent for hyperphosphatemia and particles |
| JP2019182818A (ja) * | 2018-04-17 | 2019-10-24 | ライオン株式会社 | 舌苔除去用の口腔内崩壊錠及び舌苔除去方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| US4631305A (en) | 1985-03-22 | 1986-12-23 | The Upjohn Company | Polymeric material as a disintegrant in a compressed tablet |
| DE3776116D1 (de) * | 1986-12-30 | 1992-02-27 | American Cyanamid Co | Zusammensetzung die ein polycarbophil enthaelt. |
| US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
| JPH02286621A (ja) * | 1989-04-26 | 1990-11-26 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| JPH0413627A (ja) * | 1990-04-27 | 1992-01-17 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| JP2609022B2 (ja) * | 1990-11-29 | 1997-05-14 | 北陸製薬株式会社 | ポリカルボフィルカルシウム含有製剤 |
| JPH06157325A (ja) * | 1992-11-30 | 1994-06-03 | Mitsubishi Kasei Corp | 経口コレステロール低下剤 |
| TW272942B (enExample) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
| US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| WO1996021454A1 (en) | 1995-01-12 | 1996-07-18 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| JP3836893B2 (ja) * | 1995-01-24 | 2006-10-25 | アボットジャパン株式会社 | ポリカルボフィルカルシウム含有製剤 |
| TW438608B (en) * | 1995-08-02 | 2001-06-07 | Hisamitsu Pharmaceutical Co | A tablet containing anion exchange resin |
| JP3389493B2 (ja) * | 1997-04-04 | 2003-03-24 | 中外製薬株式会社 | リン酸結合性ポリマー製剤 |
-
1998
- 1998-03-19 TW TW087104092A patent/TW592727B/zh not_active IP Right Cessation
- 1998-04-03 CA CA002286003A patent/CA2286003C/en not_active Expired - Lifetime
- 1998-04-03 ES ES98911187T patent/ES2201463T3/es not_active Expired - Lifetime
- 1998-04-03 DE DE69837945T patent/DE69837945T2/de not_active Expired - Lifetime
- 1998-04-03 EP EP02025683A patent/EP1304104B1/en not_active Expired - Lifetime
- 1998-04-03 AT AT02025683T patent/ATE364377T1/de active
- 1998-04-03 AT AT98911187T patent/ATE244013T1/de active
- 1998-04-03 WO PCT/JP1998/001536 patent/WO1998044933A1/ja not_active Ceased
- 1998-04-03 PT PT02025683T patent/PT1304104E/pt unknown
- 1998-04-03 CN CNB988046245A patent/CN1180782C/zh not_active Expired - Lifetime
- 1998-04-03 DE DE69816082T patent/DE69816082T2/de not_active Expired - Lifetime
- 1998-04-03 DK DK02025683T patent/DK1304104T3/da active
- 1998-04-03 ES ES02025683T patent/ES2287215T3/es not_active Expired - Lifetime
- 1998-04-03 KR KR10-1999-7009058A patent/KR100456202B1/ko not_active Expired - Lifetime
- 1998-04-03 US US09/381,506 patent/US6383518B1/en not_active Expired - Lifetime
- 1998-04-03 AU AU65223/98A patent/AU726142B2/en not_active Expired
- 1998-04-03 EP EP98911187A patent/EP0997148B1/en not_active Expired - Lifetime
-
2002
- 2002-03-06 US US10/090,622 patent/US6696087B2/en not_active Expired - Lifetime
-
2007
- 2007-08-23 CY CY20071101107T patent/CY1106823T1/el unknown
-
2009
- 2009-05-15 JP JP2009118371A patent/JP2009173687A/ja not_active Withdrawn
-
2012
- 2012-10-18 JP JP2012230662A patent/JP5681156B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2286003C (en) | Phosphate-binding polymer preparation | |
| KR100360053B1 (ko) | 인산결합성 폴리머 및 그것을 사용한 제제 | |
| JPWO2000022008A1 (ja) | リン酸結合性ポリマー及びそれを使用した製剤 | |
| AU778262B2 (en) | Direct compression polymer tablet core | |
| JP3389493B2 (ja) | リン酸結合性ポリマー製剤 | |
| EP2545907A1 (en) | Aqueous wet granulation process for cross-linked polyallylamine polymers | |
| JP3363143B2 (ja) | リン酸結合性ポリマー粒子 | |
| HK1027506B (en) | Phosphate-binding polymer preparations | |
| HK1055387B (en) | Tablet comprising a phosphate-binding polymer | |
| JP4749649B2 (ja) | リン酸結合性ポリマー | |
| JP2003183168A (ja) | リン酸結合性ポリマー含有製剤 | |
| JP2002265371A (ja) | リン酸結合性ポリマー製剤 | |
| CA2576135C (en) | Direct compression polymer tablet core | |
| BRPI0621323A2 (pt) | formulação farmacêutica e métodos para fabricação de polìmeros de amina alifática |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180403 |